This trial is studying the best dose and side effects of flotetuzumab for treating patients with relapsed or refractory blood cancers. Flotetuzumab is an antibody that may interfere with cancer cells' ability to grow and spread.
1 Primary · 5 Secondary · Reporting Duration: Up to 1 year
40 Total Participants · 1 Treatment Group
Primary Treatment: Flotetuzumab · No Placebo Group · Phase 1
Age Any Age · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: